This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Acasti Pharma’s 8K filing here.
Acasti Pharma Company Profile
Acasti Pharma Inc engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.
Featured Stories
- Five stocks we like better than Acasti Pharma
- Best Stocks Under $10.00
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- What Are Dividend Achievers? An Introduction
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- What is a Stock Market Index and How Do You Use Them?
- Time to Load Up on Home Builders?
